An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TEPEZZA Receives Approval in Japan to Treat TED On Sept. 24, Amgen announced that TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)....
Pregnant Women With SSD May Have Children with Developmental Delays
Pregnant women who do not get enough sleep may be at higher risk of having children with neurodevelopmental delays, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Short sleep duration (SSD) is defined as sleeping less than seven hours per night. Pregnant woman may have trouble sleeping due...
Endocrine Society Members Win 2024 Lasker~DeBakey Clinical Medical Research Award
Three Endocrine Society members have taken home the 2024 Lasker~DeBakey Clinical Medical Research Award. Joel F. Habener, MA, MD, chief of Laboratory of Molecular Endocrinology, Massachusetts General Hospital; Lotte Bjerre Knudsen, DMSc, chief scientific advisor and head of the GLP-1 Centre of Excellence at Novo Nordisk; and Svetlana Mojsov, PhD, research associate professor at Rockefeller...
Lorenzo Smith Receives FASEB’s Howard Garrison Advocacy Fellowship
Endocrine Society member Lorenzo Smith, a PhD candidate at the Huntsman Cancer Institute at the University of Utah, has been selected as a Howard Garrison Advocacy Fellow through the Federation of American Societies for Experimental Biology (FASEB). This program is designed to train and support scientists seeking opportunities to learn more about the policymaking process...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neuroendocrine Tumor Treatment Data Presented by Exelixis On September 16, Exelixis announced updated and final data from CABINET, a Phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with...
Review Examines Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
A paper recently published in Endocrine Reviews takes a look at the cardiometabolic risk in patients with congenital adrenal hyperplasia (CAH), since patients with CAH who are being treated still face numerous complications and increased mortality. The authors of the review (Krysiak et al) write that the aim of their article is to create an...
Bianco Named Vice President and Vice Provost for Research, Chief Research Officer at UTMB
Antonio Bianco, MD, PhD, has joined the University of Texas Medical Branch (UTMB) as vice president and vice provost, research, and chief research officer, effective Sept. 1. A renowned physician-scientist, scholar, and research leader, Bianco possesses an impressive academic career that includes influential contributions to the field of thyroid diseases and an enduring commitment to...
Moderate Coffee and Caffeine Consumption Linked to Lower Risk of Cardiometabolic Diseases
Consuming moderate amounts of coffee and caffeine regularly may offer a protective effect against developing multiple cardiometabolic diseases, including type 2 diabetes, coronary heart disease, and stroke, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Researchers found that regular coffee or caffeine intake, especially at moderate levels, was associated...
